Patents by Inventor Lars Jacob Stray Knutsen
Lars Jacob Stray Knutsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220133741Abstract: The present invention provides for novel combinations comprising an antihistamine with selected pharmaceutical and nutraceutical agents which alleviate some of the symptoms experienced by menopausal women, optionally combined further with a range of indole-based natural products such as L-tryptophan, 5-hydroxytryptophan and melatonin. These mixtures may be enriched further with pharmaceutically acceptable calcium and magnesium salts as well as selected B vitamins. These combinations have utility in providing a medicament for improving health in mammals, especially for the improvement of menopausal symptoms as well as sleep in women.Type: ApplicationFiled: January 17, 2022Publication date: May 5, 2022Applicant: Requis PharmaceuticalsInventors: Lars Jacob Stray Knutsen, Judith Lois Knutsen, Mark A. Pimley
-
Patent number: 11224603Abstract: The present invention provides for novel combinations comprising an antihistamine with selected pharmaceutical and nutraceutical agents which alleviate some of the symptoms experienced by menopausal women, optionally combined further with a range of indole-based natural products such as L-tryptophan, 5-hydroxytryptophan and melatonin. These mixtures may be enriched further with pharmaceutically acceptable calcium and magnesium salts as well as selected B vitamins. These combinations have utility in providing a medicament for improving health in mammals, especially for the improvement of menopausal symptoms as welt as sleep in women.Type: GrantFiled: December 13, 2014Date of Patent: January 18, 2022Assignee: REQUIS PHARMACEUTICALS, INC.Inventors: Lars Jacob Stray Knutsen, Judith Lois Knutsen, Mark A. Pimley
-
Publication number: 20190008188Abstract: The present invention provides combinations comprising a sedating antihistamine and selected indole-based natural products such as L-tryptophan, 5-hydroxytryptophan and melatonin, along with pharmaceutically acceptable calcium and magnesium salts and selected B vitamins. These combinations are useful in providing a medicament for improving sleep in mammals, especially humans.Type: ApplicationFiled: September 13, 2018Publication date: January 10, 2019Applicant: Requis PharmaceuticalsInventors: Lars Jacob Stray Knutsen, Judi Lois Knutsen
-
Publication number: 20170280749Abstract: The present invention provides combinations comprising a sedating antihistamine and selected indole-based natural products such as L-tryptophan, 5-hydroxytryptophan and melatonin, along with pharmaceutically acceptable calcium and magnesium salts and selected B vitamins. These combinations are useful in providing a medicament for improving sleep in mammals, especially humans.Type: ApplicationFiled: June 12, 2017Publication date: October 5, 2017Applicant: Requis PharmaceuticalsInventors: Lars Jacob Stray Knutsen, Judi Lois Knutsen, James M HAND
-
Patent number: 9700548Abstract: The present invention provides combinations comprising a sedating antihistamine and selected indole-based natural products such as L-tryptophan, 5-hydroxytryptophan and melatonin, along with pharmaceutically acceptable calcium and magnesium salts and selected B vitamins. These combinations are useful in providing a medicament for improving sleep in mammals, especially humans.Type: GrantFiled: June 8, 2012Date of Patent: July 11, 2017Assignee: REQUIS PHARMACEUTICALS INC.Inventors: Lars Jacob Stray Knutsen, Judi Lois Knutsen
-
Publication number: 20160317554Abstract: The present invention provides for novel combinations comprising an antihistamine with selected pharmaceutical and nutraceutical agents which alleviate some of the symptoms experienced by menopausal women, optionally combined further with a range of indole-based natural products such as L-tryptophan, 5-hydroxytryptophan and melatonin. These mixtures may be enriched further with pharmaceutically acceptable calcium and magnesium salts as well as selected B vitamins. These combinations have utility in providing a medicament for improving health in mammals, especially for the improvement of menopausal symptoms as welt as sleep in women.Type: ApplicationFiled: December 13, 2014Publication date: November 3, 2016Applicant: Requis Pharmaceuticals, Inc.Inventors: Lars Jacob Stray Knutsen, Judith Lois Knutsen, Mark A. Pimley
-
Publication number: 20160008334Abstract: The present invention is directed to combinations of sedating antihistamines and at least one, and preferably two or more dietary supplements, which can be indole-based, such as tryptophan, 5-hydroxytryptophan, serotonin, N-acetyl-5-hydroxytryptamine and melatonin, and to their use for treating and thereby improving the health and quality of life of those suffering from sleep-related respiratory disorders, characterized by abnormal breathing during sleep. These include snoring, sleep disordered breathing, sleep apneas, upper airway resistance syndrome, obstructive sleep apnea, central sleep apnea and obesity hypoventilation syndrome and associated ailments.Type: ApplicationFiled: March 5, 2014Publication date: January 14, 2016Applicant: REQUIS PHARMACEUTICALS INC.Inventors: Lars Jacob Stray Knutsen, James M. Hand
-
Publication number: 20150125548Abstract: The present invention is directed to nutritional and nutraceutical compositions which comprise novel mixtures of two or more indole-based dietary supplements such as L-tryptophan and melatonin, together with selected minerals and vitamins that stimulate tryptophan metabolism in the direction of serotonin and melatonin, and to their use in a preferred embodiment of the invention in a readily ingested beverage form, optionally combined with a range of other natural ingredients designed to improve the health and state of mind of human subjects. Alternative dosage forms, such as tablets for oral dosing, and dosage forms for buccal and sublingual administration, including thin films, are also incorporated in the present invention. Health improvements include the treatment of disorders of circadian rhythm, such as shift work disorder and jet lag, the induction of relaxation and a restful frame of mind, as well as providing restorative sleep function.Type: ApplicationFiled: November 13, 2012Publication date: May 7, 2015Applicant: Requis Pharmaceuticals Inc.Inventors: Lars Jacob Stray Knutsen, Judi Lois Knutsen
-
Publication number: 20140199417Abstract: The present invention provides combinations comprising a sedating antihistamine and selected indole-based natural products such as L-tryptophan, 5-hydroxytryptophan and melatonin, along with pharmaceutically acceptable calcium and magnesium salts and selected B vitamins. These combinations are useful in providing a medicament for improving sleep in mammals, especially humans.Type: ApplicationFiled: June 8, 2012Publication date: July 17, 2014Applicant: Requis Pharmaceuticals Inc.Inventors: Lars Jacob Stray Knutsen, Judi Lois Knutsen
-
Publication number: 20140080787Abstract: The present invention relates to compositions and methods for the treatment, prevention, and diagnosis of neuropathies due to PMP22 mis-expression in a subject having Charcot-Marie-Tooth disease, especially Charcot-Marie-Tooth 1A disease. The present invention incorporates the use of small molecule proteasome inhibitors such as, but not limited to, Bortezomib to inhibit or reduce the overexpression of the PMP2 gene.Type: ApplicationFiled: September 13, 2013Publication date: March 20, 2014Inventors: James Inglese, John Peter Svaren, Sung-Wook Jang, Mark Albert Scheideler, Lars Jacob Stray Knutsen
-
Patent number: 6608085Abstract: Use of a compound of formula (I) as defined herein, or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2a receptors, may be beneficial, such as a movement disorder, for example, Parkinson's Disease or progressive supemuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorder-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity, Alzheimer's disease or other disorders of the basal ganglia which result in dyskinesias.Type: GrantFiled: May 9, 2001Date of Patent: August 19, 2003Assignee: Vernalis Research LimitedInventors: Roger John Gillespie, Joanne Lerpiniere, Paul Richard Giles, David Reginald Adams, Lars Jacob Stray Knutsen, Ian Anthony Cliffe
-
Patent number: 6583156Abstract: Use a compound of formula (I) wherein: R1 is hydrogen or alkyl; R2 and R3 are independently selected from hydrogen, alkyl, aryl and heterocyclyle or together may form a ring or R1 and R2 or R3 together may form an oxygen-containing, optionally fused ring pharmaceutically acceptable salts or prodrugs thereof, with the proviso that where R1 and R4 to R9 are hydrogen, R2 or R3 is not 3-methoxy-4-benzyloxyphenyl or 2-dimethylaminoethoxymethyl, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial.Type: GrantFiled: May 16, 2001Date of Patent: June 24, 2003Assignee: Vernalis Research LimitedInventors: Roger John Gillespie, Joanne Lerpiniere, Suneel Gaur, David Reginald Adoms, Lars Jacob Stray Knutsen, Simon Edward Ward
-
Patent number: 6197788Abstract: The present invention relates to the use of (±)-R*,S*)-alpha-2-piperidnyl-2,8-bis(trifluoromethyl)-4-quinolinemthanol and in particular (−)-(11S,2′R)-alpha-2-piperidnyl-2,8-bis(trifluoromethyl)-4-quinolinemthanol in the treatment of disorders in which the reduction of purinergic neurotransmission could be beneficial. The invention relates in particular to adenosine receptors, and particularly adenosine A2a receptors and to the treatment of movement disorders such as Parkinson's disease.Type: GrantFiled: September 27, 1999Date of Patent: March 6, 2001Assignee: Vernalis Research LimitedInventors: Allan Fletcher, Lars Jacob Stray Knutsen, Richard H. P. Porter, Scott Murray Weiss, Robin Shepherd
-
Patent number: 5683989Abstract: The present invention relates to compounds of formula I ##STR1## wherein X is amino, C.sub.1-6 -alkylamino, di-C.sub.1-6 -alkylamino;R.sup.1 is H, straight or branched C.sub.1-6 -alkyl or trifluoromethyl; R.sup.4 is H or straight or branched C.sub.1-6 -alkyl; or R.sup.1 and R.sup.4 together form a cyclobutyl, cyclopentyl or cyclohexyl ring;Y is O, S, SO.sub.2, N--H or N-alkyl;R.sup.5 is selected from optionally substituted heterocycles;R.sup.6 is hydrogen, benzoyl or C.sub.1-6 -alkanoyl andR.sup.7 is hydrogen, benzoyl or C.sub.1-6 -alkanoyl; ora pharmaceutically acceptable salt thereof.The compounds have been found useful for treating central nervous system and cardiovascular ailments.Type: GrantFiled: July 20, 1995Date of Patent: November 4, 1997Assignee: Novo Nordisk A/SInventors: Jesper Lau, Lars Jacob Stray Knutsen, Malcolm Sheardown, Anker Jon Hansen
-
Patent number: 5672588Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## wherein X is hydrogen, amino, halogen, hydroxy, lower alkoxy or lower alkyl andR.sup.1 is ##STR2## wherein Y is methylene or a valence bond, R.sup.2 and R.sup.5 is H or lower, straight or branched alkyl,R.sup.3 is H or lower alkyl, orR.sup.2 and R.sup.3 can together form a cyclobutyl, cyclopentyl, cyclohexyl or phenyl ring,Z is oxygen, methylene, sulphur, sulphonyl or a valence bond,R.sup.4 is H, lower alkyl, aralkyl, a mono or bicyclic aromatic system optionally substituted with various groups.The compounds have been found useful for treating central nervous system ailments.Type: GrantFiled: August 28, 1995Date of Patent: September 30, 1997Assignee: Novo Nordisk A/SInventors: Lars Jacob Stray Knutsen, Jesper Lau